Scandinavian ChemoTech AB Series B Working Capital to Net Assets Ratio
Scandinavian ChemoTech AB Series B working capital to net assets ratio. Scandinavian ChemoTech AB Series B (CMOTEC-B) has a Working Capital to Net Assets ratio of -117.0% as of June 2026. Working capital of Skr-1.78 Million (current assets of Skr7.71 Million minus current liabilities of Skr9.49 Million) is measured against net assets of Skr1.52 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Scandinavian ChemoTech AB Series B tangible net worth ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Scandinavian ChemoTech AB Series B (2014–2025)
Working capital to net assets ratio of Scandinavian ChemoTech AB Series B from 2014 to 2025. This chart shows how Scandinavian ChemoTech AB Series B's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2014 to 2025. As of June 2026, the ratio stands at -117.0%, reflecting working capital of Skr-1.78 Million against net assets of Skr1.52 Million SEK. See Scandinavian ChemoTech AB Series B (CMOTEC-B) liquidity interval to measure how many days the company can operate on defensive assets alone.
Scandinavian ChemoTech AB Series B Working Capital to Net Assets Ratio by Year (2014–2025)
Scandinavian ChemoTech AB Series B working capital to net assets ratio by year from 2014 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Scandinavian ChemoTech AB Series B from 2014 to 2025, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see CMOTEC-B total assets.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -27.5% | Skr-876.00K | Skr3.19 Million | Skr9.14 Million | Skr10.01 Million | ▼ -33.7 pp |
| 2024 | 6.2% | Skr370.00K | Skr5.98 Million | Skr7.77 Million | Skr7.40 Million | ▼ -24.3 pp |
| 2023 | 30.5% | Skr3.36 Million | Skr11.03 Million | Skr7.20 Million | Skr3.84 Million | ▲ +1.1 pp |
| 2022 | 29.4% | Skr4.11 Million | Skr13.99 Million | Skr11.82 Million | Skr7.71 Million | ▼ -18.9 pp |
| 2021 | 48.3% | Skr11.54 Million | Skr23.92 Million | Skr13.44 Million | Skr1.89 Million | ▲ +76.1 pp |
| 2020 | -27.8% | Skr-2.57 Million | Skr9.24 Million | Skr4.13 Million | Skr6.70 Million | ▼ -6.3 pp |
| 2019 | -21.6% | Skr-2.10 Million | Skr9.73 Million | Skr5.53 Million | Skr7.63 Million | ▼ -52.2 pp |
| 2018 | 30.6% | Skr6.27 Million | Skr20.50 Million | Skr8.29 Million | Skr2.02 Million | ▼ -0.6 pp |
| 2017 | 31.2% | Skr3.21 Million | Skr10.29 Million | Skr5.32 Million | Skr2.11 Million | ▼ -40.3 pp |
| 2016 | 71.5% | Skr10.43 Million | Skr14.58 Million | Skr12.15 Million | Skr1.72 Million | ▲ +235.9 pp |
| 2015 | -164.4% | Skr-1.43 Million | Skr868.64K | Skr3.61 Million | Skr5.03 Million | ▼ -219.2 pp |
| 2014 | 54.7% | Skr25.33K | Skr46.27K | Skr44.96K | Skr19.63K | — |